STOCK TITAN
  1. Home
  2. News
  3. GANX

Gain Therapeutics, Inc. - GANX STOCK NEWS

Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.

Gain Therapeutics, Inc. (NASDAQ: GANX) is a pioneering biotechnology company committed to the discovery and development of novel small molecule therapeutics. Specializing in addressing rare genetic diseases, Gain Therapeutics focuses on orphan diseases caused by inborn errors of metabolism. With a strong emphasis on lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology, the company's innovative approach aims to provide solutions where there is a high unmet medical need.

At the forefront of Gain Therapeutics' pipeline is GT-02287, a promising clinical-stage product candidate targeting GBA1 Parkinson's disease. Currently in Phase 1 clinical trials, GT-02287 is designed to be a disease-modifying treatment. It functions as an allosteric protein modulator to restore the activity of the lysosomal enzyme glucocerebrosidase (GCase), tackling the underlying cause of disease rather than just alleviating symptoms.

The company's proprietary Magellan™ platform leverages AI-supported structural biology and advanced algorithms to discover novel allosteric binding sites on disease-implicated proteins. This innovative computational technology identifies potential small molecules that can bind to these sites, offering new avenues for therapeutic development. Magellan builds upon Gain’s original SEE-Tx® platform, enhancing it with AI and virtual screening capabilities to explore vast chemical spaces.

Recent achievements highlight Gain Therapeutics' impact on the biotech landscape. Data presented at the 20th WORLDSymposium™ showcased the progressive reversal of motor deficits in preclinical models, alongside a significant reduction of neurodegeneration biomarkers. This underscores the potential of GT-02287 as a best-in-class treatment for neurodegenerative diseases.

Gain Therapeutics collaborates with notable organizations including The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation for Parkinson’s with GBA. These partnerships provide essential support and validation for the company's mission to transform therapeutic landscapes with innovative treatments.

For more information, visit GainTherapeutics.com and follow their updates on LinkedIn.

News

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) to hold a 2024 Research & Development update on February 22, 2024, focusing on GT-02287 in vivo data for Parkinson's Disease. Key Opinion Leaders to provide insights on unmet medical needs and therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
News

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) presents preclinical data at the 20th WORLDSymposium™, demonstrating the neuroprotective effects and motor function restoration of its clinical-stage GCase regulator GT-02287 in Parkinson's disease models. The data show a progressive reversal of motor deficit and a reduction of the neurodegeneration biomarker NfL to the level of the control arm. The company is currently conducting a Phase 1 clinical trial of GT-02287 in healthy adults and plans to commence treatment of patients in an extension of that clinical trial in Q3 of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
News

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

Rhea-AI Summary
Gain Therapeutics, Inc. releases a letter to stockholders from its CEO, Matthias Alder, highlighting the progress of the company in 2023 and its strategy for 2024. They focus on the development of their lead drug candidate for Parkinson's disease, GT-02287, and present preclinical data supporting its potential. Additionally, they discuss the upgrade of their computational drug discovery platform, Magellan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced new data of GT-02287 in preclinical models of Parkinson’s disease accepted for a platform presentation at the 20th Annual WORLDSymposium™. The presentation will focus on GT-02287, a clinical stage GCase enhancer, displaying neuroprotection and restoring motor function in preclinical models of Parkinson’s disease following delayed administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
none
-
News

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Matthias Alder's participation in a fireside chat with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research on December 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
conferences
-
News

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators with therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. The study was published in PLOS ONE and demonstrated the potential of allosteric modulators as a therapeutic option for hard-to-treat genetic diseases where there are no effective approaches for disease modification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
clinical trial
News

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Matthias Alder will participate in a panel at the AI Driven Drug Discovery Summit on December 6, 2023. The event will focus on collaboration in AI-driven drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
conferences AI
-
News

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

Rhea-AI Summary
Gain Therapeutics, Inc. (Gain) (Nasdaq: GANX) closed an underwritten public offering of 2,545,000 shares of common stock and warrants to purchase up to 1,272,500 shares at a combined public offering price of $2.005 per share and accompanying warrant. In a private placement, Gain issued 2,500,088 shares of common stock and warrants to purchase up to 2,500,088 shares at an offering price of $2.00 per share. The gross proceeds from the offerings were approximately $10.1 million, excluding underwriting and placement agent discounts and commissions and other offering-related expenses. Gain intends to use the net proceeds for the development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
offering
-
News

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $2.75 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. In connection with the offering, Gain has granted the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock and/or warrants to purchase shares of common stock at the public offering price, less underwriting discounts and commissions. In a private placement to be completed concurrently with the completion of the public offering, Gain will issue to an accredited investor an aggregate of 2,500,088 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,500,088 shares of common stock. The offering price per share and accompanying warrant sold in the private placement is $2.00. The warrants issued in the private placement will be exercisable at an exercise price of $2.75 per share, will be exercisable beginning six months after issuance and will expire five years from the date of issuance. Newbridge Securities Corporation is acting as the sole book-running manager for the public offering and as placement agent for the private placement. Allele Capital Partners, LLC is acting as Financial Advisor to Gain. Gain expects to receive aggregate gross proceeds from the public and private offering, excluding the exercise of the underwriters’ option, if any, of approximately $9.4 million, excluding underwriting and placement agent discounts and commissions and other offering-related expenses. The offerings are expected to close on or before November 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.9%
Tags
offering
News

Gain Therapeutics Announces Proposed Public Offering

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) Proposes Public Offering to Fund Neurodegenerative Disease Treatment Development. Gain Therapeutics, Inc. announced a proposed public offering of its common stock and warrants to fund the development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease. The offering is subject to market conditions, and the company expects to use the net proceeds for clinical and nonclinical development as well as general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.9%
Tags
offering

FAQ

What is the current stock price of Gain Therapeutics (GANX)?

The current stock price of Gain Therapeutics (GANX) is $1.56 as of December 20, 2024.

What is the market cap of Gain Therapeutics (GANX)?

The market cap of Gain Therapeutics (GANX) is approximately 42.1M.

What is Gain Therapeutics, Inc.?

Gain Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule therapeutics for rare genetic diseases and other serious conditions.

What diseases is Gain Therapeutics targeting?

The company targets lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology, with a focus on GBA1 Parkinson's disease.

What is GT-02287?

GT-02287 is a clinical-stage product candidate being developed by Gain Therapeutics for the treatment of GBA1 Parkinson's disease. It aims to restore the function of the enzyme glucocerebrosidase (GCase).

How does Gain Therapeutics discover new treatments?

The company uses its proprietary Magellan™ platform, which combines AI-supported structural biology and advanced algorithms to identify novel allosteric binding sites on proteins.

What recent achievements has Gain Therapeutics made?

Recent data presented at the 20th WORLDSymposium™ showed the potential of GT-02287 to reverse motor deficits and reduce neurodegeneration biomarkers in preclinical models.

Who are Gain Therapeutics' partners?

Gain Therapeutics collaborates with organizations such as The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation for Parkinson’s with GBA.

What is the Magellan™ platform?

Magellan™ is Gain Therapeutics' proprietary platform that uses AI and advanced algorithms to discover novel allosteric binding sites on disease-implicated proteins, leading to the identification of new therapeutic compounds.

What is unique about Gain Therapeutics' approach?

Gain Therapeutics' approach is unique because it focuses on allosteric modulation to restore or disrupt protein function, offering potential treatments for diseases that are currently untreatable or difficult to treat.

How does GT-02287 work?

GT-02287 works by modulating the function of the lysosomal enzyme glucocerebrosidase (GCase), which is impaired in GBA1 Parkinson's disease, helping to address the underlying cause of the disease.

Where can I find more information about Gain Therapeutics?

For more information about Gain Therapeutics, visit their website at GainTherapeutics.com or follow their updates on LinkedIn.

Stock GANX logo
Gain Therapeutics, Inc.

Nasdaq:GANX

GANX Rankings

#4960 Ranked by Market Cap
N/A Ranked by Dividends

GANX Stock Data

42.15M
25.22M
5.09%
7.96%
2.58%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BETHESDA